Navigation Links
Venaxis to Present at Piper Jaffray 25th Annual Healthcare Conference
Date:11/21/2013

CASTLE ROCK, Colo., Nov. 21, 2013 /PRNewswire/-- Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance and commercializing its CE Marked APPY1™ Test, a rapid, multiple biomarker-based assay for identifying patients that are at low risk for appendicitis, today announced it will present at the Piper Jaffray 25th Annual Healthcare Conference, to be held December 3-4, 2013, at The New York Palace Hotel in New York, NY. 

Steve Lundy, President and CEO of Venaxis™, will provide an overview of the Company's business during his live presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.  Event:Piper Jaffray 25th Annual Healthcare ConferenceDate:Tuesday, December 3, 2013 Time:9:30 am (Eastern Time) Location: 

The New York Palace Hotel, New York, NY The presentation will be webcast live.  To access the webcast, please visit the investor relations section of the Venaxis website at http://ir.venaxis.com. The webcast will be archived and available for 90 days.

Separately, Venaxis is scheduled to ring The NASDAQ Stock Market Closing Bell on December 6, 2013 in a ceremony to celebrate the company's recent achievements as it advances the APPY1 Test toward potential FDA clearance and expands its commercial footprint in the EU.  Venaxis remains on track to complete patient enrollment for its pivotal clinical study of the APPY1 Test in the United States at or around the end of 2013.

About Venaxis, Inc.
Venaxis, Inc. is an in vitro diagnostic company focused on the clinical development and commercialization of its CE Marked APPY1 Test, the Company's rapid, protein biomarker-based assay for appendicit
'/>"/>

SOURCE Venaxis, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Venaxis APPY1 Test Passes Futility Analysis in Pivotal Clinical Study
2. Venaxis Announces Pricing of Offering of Common Stock and Warrants
3. Venaxis Executes First Commercial Development Agreement and Receives Purchase Order from EMELCA Bioscience for Initial EU Launch
4. Dyadic International To Present At Two Major Conferences In December 2013
5. Sangamo BioSciences Announces Seven Data Presentations At The 2013 American Society of Hematology Annual Meeting
6. Aratana Therapeutics to Present at Two Upcoming Investor Conferences
7. Celladon Corporation Announces Oral Presentation at American Heart Association of Long Term Follow-Up Results from the MYDICAR CUPID 1 Trial in Advanced Heart Failure
8. Amgen Presents Interim Overall Survival Data From Phase 3 Study Of Talimogene Laherparepvec In Patients With Metastatic Melanoma
9. Accuray to Present at Piper Jaffray 25th Annual Healthcare Conference
10. Cartes 2013: DERMALOG Presents World Firsts in Biometrics
11. Proove Biosciences to Present Research on the Genetics of Pain Medicine and Exhibit at ASRA’s 12th Annual Pain Medicine Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Switzerland (PRWEB) January 22, 2015 Selexis ... characterized mammalian Research Cell Banks (RCBs) used for drug ... Research Cell Banks will include Next-Generation Sequencing ... genetic architecture de-risks biologic manufacturing by ensuring the integrity ...
(Date:1/22/2015)... , Jan. 22, 2015   GenoSpace , a precision medicine ... to enable the broad use of genomic, imaging and other ... appointment of Michelle Munson , CEO of Aspera, an ... Logo - http://photos.prnewswire.com/prnh/20150122/170713 "We ...
(Date:12/24/2014)... , Dec. 24, 2014  Vermillion, Inc. (Nasdaq:   ... disease, announced today that the Company closed its ... Investment Management, Jack W. Schuler , Birchview ... were $10.5 million, before offering expenses.  The proceeds ...
(Date:12/24/2014)... SoundConnect’s 2015 next generation ... communication technology, provide continued education and inform users ... demonstrates online communication features and benefits; empowering users ... innovative and powerful tools. , According to SoundConnect’s ...
Breaking Biology Technology:Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2GenoSpace Expands Board with Appointment of Michelle Munson 2Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3SoundConnect Launches Leading Edge Business Communications Webinar Series 2SoundConnect Launches Leading Edge Business Communications Webinar Series 3
... Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) announced ... has granted fast track designation for carfilzomib, a next ... with relapsed and refractory multiple myeloma. The Fast Track ... the development, and expedite the review of drugs to ...
... SAN FRANCISCO, Jan. 31, 2011 DNA Direct, a ... MHS ) and a leading provider of ... that Aspirus Wausau Hospital of Wausau, Wisconsin, Atlantic Health ... Rochester, Michigan and Swedish Covenant Hospital of Chicago, Illinois, ...
... Frontier Global Sciences, a leading scientific laboratory ... today it has expanded its capabilities to include ... instrument. The purchase of a Perkin Elmer Nexion ... ICP-MS services including standard quadropole, true dynamic reaction ...
Cached Biology Technology:Onyx Pharmaceuticals Receives Fast Track Designation for Carfilzomib; Company Initiates Rolling NDA Submission for Accelerated Approval 2Onyx Pharmaceuticals Receives Fast Track Designation for Carfilzomib; Company Initiates Rolling NDA Submission for Accelerated Approval 3Onyx Pharmaceuticals Receives Fast Track Designation for Carfilzomib; Company Initiates Rolling NDA Submission for Accelerated Approval 4Four Community Hospitals Join DNA Direct's Genomic Medicine Network 2Four Community Hospitals Join DNA Direct's Genomic Medicine Network 3
(Date:12/17/2014)... , Dec. 15, 2014  HITLAB SM announced today ... to confirm its adherence to current U.S. Food and ... conduct regulated smart device and smart phone application trials ... quality. "HITLAB is determined to improve global ...
(Date:12/17/2014)... Dec. 16, 2014 Research and Markets ( ... "Global Chemical Sensor Market 2015-2019" report to their ... One major trend upcoming in this market is ... Chemical sensors help in recording of patient data for ...
(Date:12/15/2014)... , Dec. 12, 2014 Research and Markets ... "Global Facial Recognition Market 2015-2019" report to ... Facial recognition is a technology used for ... overall facial feature of a person such as nose, ...
Breaking Biology News(10 mins):HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3
... Soybean production has continued to increase in the Northeast ... the crop and many experienced growers planting alongside corn crops. ... with a corn planter in 30-inch rows instead of 7.5-inch ... a Cornell University scientist, investigated the response of two soybean ...
... L. Boren announced today that OU is establishing an ... expertise to benefit Oklahoma and the nation, including emerging ... led by a national expert, who will be appointed ... million gift from Corix, a multi-utility infrastructure company, which ...
... grant totaling $2.2 million shows how the University of ... using technology to advance the cutting-edge field of personalized ... their genetic make-up. The grant also highlights the ... Institute (CCTSI) to bring scientific discoveries to the bedside ...
Cached Biology News:OU establishes a new water and sustainability institute 2OU establishes a new water and sustainability institute 3Personalizing medicine 2Personalizing medicine 3